Eric Hoffman, PhD
Dr. Hoffman is a human geneticist and translational researcher focused on neuromuscular disease, and skeletal muscle tissue in health and disease. His most recent efforts focus on drug development and clinical trials in Duchenne muscular dystrophy. He received his PhD in Drosophila molecular genetics from Johns Hopkins University, was a post-doc at Boston Children’s Hospital and Harvard Medical School working on the identification of the DMD gene and protein, then led academic research groups at Harvard, University of Pittsburgh, and Children’s National Medical Center. Currently, he is Associate Dean for Research, School of Pharmacy and Pharmaceutical Sciences, Binghamton University – SUNY, where he is building a research program focused on facilitating drug development at the academic/industry interface. In the private sector, he is co-founder and CEO of ReveraGen Biopharma, co-founder and Vice President of AGADA Biosciences, and co-founder and President of TRiNDS LLC; each company focuses on different aspects of orphan drug development. He serves on Scientific Advisory Boards of Foundation to Eradicate Duchenne, CureDuchenne Foundation, C3 Foundation, Save Our Sons Foundation, and Duchenne UK. Research accomplishments include identification of the dystrophin protein, developing molecular diagnostic methods for neuromuscular patients and families, defining the molecular pathophysiology of different types of muscular dystrophies, and development of experimental therapeutics approaches. His lab also identified the first voltage sensitive ion channel mutations in human disease, and first genetic causes of recurrent pregnancy loss. He is an inventor on nine patents, and has authored over 500 publications.